Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue

Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue Gilead Sciences Inc. (NASDAQ:GILD) has taken the decision to limit the number of patients it admits to its support path patient assistance program. The decision only affects those patients seeking … Continue reading

Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' HepatitisC

Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' Hepatitis–C For Gilead, the company's HCV launch in the U.S. has stagnated but there is still plenty of opportunity for ex-U.S. growth. As payors still won't let HCV patients flow through the … Continue reading